Pain Therapeutics Inc. is seeking to assure the market that its oxycodone abuse-resistant extended-release drug Remoxy is still on track for resubmission to FDA despite Pfizer Inc.’s decision to end a development and commercialization agreement for the product.
In an Oct. 27 conference call Pain Therapeutics President and CEO Remi Barbier said that on Friday, Pfizer verbally shared the preliminary top-line results of five clinical studies it conducted...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?